APOGEPHA Arzneimittel GmbH
Quick facts
Marketed products
Phase 3 pipeline
- Mictonetten 5 mg, coated tablet · Urology
Mictonetten is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about APOGEPHA Arzneimittel GmbH
What are APOGEPHA Arzneimittel GmbH's marketed drugs?
Top marketed products include propiverine hydrochloride.
What is APOGEPHA Arzneimittel GmbH's pipeline?
APOGEPHA Arzneimittel GmbH has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Mictonetten 5 mg, coated tablet.